$15M Fund Aims to Transform Celiac Disease Diagnosis

Seventy percent of people with celiac disease have no idea they're living with it, but a new $15 million fund could change that reality for millions.

The Celiac Disease Foundation announced its Impact Fund this week, partnering with Triple G Ventures to invest directly in breakthrough technologies that could transform how we detect, prevent, and potentially cure this widespread autoimmune condition. Unlike traditional charity donations, every dollar returned from successful investments flows back into funding the next wave of innovation.

Celiac disease affects one in 100 people worldwide, yet most cases go undiagnosed for years or even decades. Without proper treatment, people face serious complications including bone loss, infertility, nerve damage, and certain cancers, all while wondering why they feel so sick.

The fund will pour money into four promising areas. At-home testing kits and AI screening tools could catch the disease years earlier. Microbiome therapies might prevent it from developing in the first place. Better education platforms will help doctors recognize symptoms they're currently missing. And experimental treatments like enzyme therapies and immune tolerance approaches could one day offer actual cures instead of just lifelong dietary restrictions.

Gregg Stein, who leads the fund at Triple G Ventures, knows this struggle personally. His wife received her diagnosis at 43, after years of unexplained health problems. "I've seen firsthand how deeply it disrupts daily life," he said, explaining why the fund focuses on speed and scale.

The funding gap has held back progress for decades. Celiac disease research receives far less money than other autoimmune conditions, even though it affects millions. An independent committee will evaluate which companies and technologies get funded, prioritizing solutions that combine solid science with real-world viability.

The Ripple Effect

This fund does more than help people with celiac disease avoid gluten. It creates a model for how patient communities can drive innovation when traditional funding falls short. The venture philanthropy approach means successful investments multiply their impact, creating a self-sustaining engine that keeps accelerating progress long after the initial $15 million is deployed.

Every breakthrough in detection makes diagnosis faster and cheaper for everyone. Every prevention strategy tested brings us closer to stopping autoimmune diseases before they start. And every promising treatment that reaches clinical trials opens doors for similar conditions affecting millions more people worldwide.

For the three million Americans currently navigating life with undiagnosed celiac disease, this fund represents something powerful: proof that their wait for answers is finally being met with the urgency it deserves.